ArticleCureus2025
Evaluating the Impact of Retroperitoneal Lymphadenectomy in Terms of Morbidity and Survival in Advanced Epithelial Ovarian Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background This study aims to assess the role of routine systematic retroperitoneal lymphadenectomy (RPLND) in managing advanced ovarian cancer while maintaining acceptable levels of morbidity and without mortality associated with the procedure. However, concerns have emerged regarding its insufficiency in delivering survival benefits. Method A retrospective analysis of prospectively maintained electronic records from 2012 to 2023 was conducted at our tertiary referral center among 362 cases of advanced ovarian cancer. Patients with International Federation of Gynecology and Obstetrics (FIGO) stages III and IV cancer underwent optimal cytoreductive surgery (CRS) with standard upfront and interval procedures, including systematic RPLND, and selected cases underwent hyperthermic intraperitoneal chemotherapy (HIPEC). We analyzed RPLND-associated morbidity, encompassing both intraoperative and postoperative complications. Result The mean age of the patients was 55.2 years. The lymph nodes were found to be positive in 215 patients (59.39%), and the positivity rate was higher in those who underwent upfront surgery (n=139; 64.65%), as compared to those who received neoadjuvant chemotherapy (NACT; n=76; 35.35%). RPLND-related post-operative complications were vascular: inferior vena cava (IVC) injury (n=10; 2.76%), aortic injury (n=6; 1.6%), and lymphatic leaks in the postoperative period (n=21; 5.80%) patients. Out of these 21 patients, some developed lymphatic ascites (n=13; 3.59%), chylous ascites (n=8; 2.4%), and postoperative ileus (n=12; 3.32%). Recurrence was reported 104 patients (39.69%) during the follow-up period. For a median follow-up of 58.5 months, the median disease-free survival (DFS) was 32.3 months. The overall five-year survival in our patients was 48.9% (95% CI 35.5-61). Conclusion RPLND in advanced ovarian cancer was feasible, revealed high nodal positivity (>50%), and was associated with manageable morbidity without mortality. It facilitates precise disease staging and helps achieve optimal cytoreduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.